What's in Orexo AB's pipeline?

Orexo AB has 5 drugs in our index: 2 marketed, 0 filed, 3 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Orexo AB's portfolio?

Top competitors by shared drug class: Rutgers, The State University of New Jersey, Indivior Inc., Merck Sharp & Dohme LLC, New York State Psychiatric Institute, Fox Chase Cancer Center.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/orexo-ab.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Orexo AB — Portfolio Competitive Intelligence Brief

Orexo AB pipeline: 2 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
SL fentanyl	SL fentanyl	marketed
Higher bioavailability BNX sublingual tablets	Higher bioavailability BNX sublingual tablets	marketed	Opioid partial agonist	Mu-opioid receptor (μ-OR)	Pain management; Opioid use disorder
Buprenorphine/naloxone sublingual tablets	Buprenorphine/naloxone sublingual tablets	phase 3	Opioid agonist-antagonist combination	Mu-opioid receptor (buprenorphine partial agonist; naloxone antagonist)	Psychiatry / Addiction Medicine
BNX sublingual tablets	BNX sublingual tablets	phase 3	Partial mu-opioid receptor agonist	Mu-opioid receptor (OPRM1)	Pain Management / Addiction Medicine
BNX sublingual film	BNX sublingual film	phase 3	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)	Pain Management / Addiction Medicine

Therapeutic area mix

Pain Management / Addiction Medicine · 2
Pain management; Opioid use disorder · 1
Psychiatry / Addiction Medicine · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Rutgers, The State University of New Jersey · 2 shared drug classes
Indivior Inc. · 2 shared drug classes
Merck Sharp & Dohme LLC · 2 shared drug classes
New York State Psychiatric Institute · 2 shared drug classes
Fox Chase Cancer Center · 1 shared drug class
Friends Research Institute, Inc. · 1 shared drug class
Brigham and Women's Hospital · 1 shared drug class
Elite Laboratories, Inc · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Orexo AB:

Cite this brief

Drug Landscape (2026). Orexo AB — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/orexo-ab. Accessed 2026-05-14.